Drug Trial Radar · NCT05469646
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated
Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 3, 2022
Primary completion
Dec 20, 2022
Study completion Dec 27, 2022
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1819479 in healthy male Japanese subjects receiving single rising doses (SRD) in order to provide the basis for a clinical development of BI 1819479 in Japan.
Conditions
- Healthy
Interventions
BI 1819479Drug
BI 1819479
Matching placeboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: Up to 64 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SOUSEIKAI Sumida Hospital
Tokyo, Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.